{"protocolSection":{"identificationModule":{"nctId":"NCT02438423","orgStudyIdInfo":{"id":"2015 TIV-MNP"},"organization":{"fullName":"Georgia Institute of Technology","class":"OTHER"},"briefTitle":"Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle","officialTitle":"A Phase I Study of the Safety, Reactogenicity, Acceptability and Immunogenicity of Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle"},"statusModule":{"statusVerifiedDate":"2019-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-06"},"primaryCompletionDateStruct":{"date":"2016-03-23","type":"ACTUAL"},"completionDateStruct":{"date":"2016-03-23","type":"ACTUAL"},"studyFirstSubmitDate":"2015-05-06","studyFirstSubmitQcDate":"2015-05-07","studyFirstPostDateStruct":{"date":"2015-05-08","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-02-27","resultsFirstSubmitQcDate":"2019-04-12","resultsFirstPostDateStruct":{"date":"2019-07-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-04-12","lastUpdatePostDateStruct":{"date":"2019-07-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Mark Prausnitz","investigatorTitle":"Investigator","investigatorAffiliation":"Georgia Institute of Technology"},"leadSponsor":{"name":"Mark Prausnitz","class":"OTHER"},"collaborators":[{"name":"Emory University","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Title: A Phase I Study of The Safety, Reactogenicity, Acceptability and Immunogenicity of Inactivated Influenza Vaccine Delivered either by Microneedle Patch or by Hypodermic Needle.\n\nThis is a single center, partially blinded, randomized phase I study in which healthy adult subjects (ages 18-49) will receive either inactivated influenza vaccine (IIV) (either by microneedle patch or hypodermic needle) or placebo (by microneedle patch). This study is designed to investigate the safety, reactogenicity, acceptability and immunogenicity of an inactivated influenza vaccine delivered by microneedle patch.","detailedDescription":"Title: A Phase I Study of The Safety, Reactogenicity, Acceptability and Immunogenicity of Inactivated Influenza Vaccine Delivered either by Microneedle Patch or by Hypodermic Needle.\n\nPopulation: healthy adults, 18-49 years inclusive\n\nNumber of Sites: One\n\nStudy Duration: 12 months\n\nSubject Duration: 6 months\n\nObjectives:\n\nPrimary:\n\nTo evaluate the safety and reactogenicity following receipt of inactivated influenza vaccine delivered by microneedle patch (either by staff or self-administered).\n\nSecondary:\n\nTo evaluate the HAI titers following receipt of inactivated influenza vaccine delivered either by microneedle patch or by hypodermic needle (both vaccines administered by study staff).\n\nTo evaluate unsolicited adverse events following receipt of IIV delivered by microneedle patch (administered by study staff or self-administered).\n\nTo evaluate new-onset chronic illnesses (NOCI) following receipt of IIV delivered by microneedle patch (administered by study staff or self-administered).\n\nExploratory:\n\nTo evaluate microneutralizing antibody titers following receipt of inactivated influenza vaccine delivered either by microneedle patch or by hypodermic needle (both vaccines administered by study staff).\n\nTo evaluate HAI +/- microneutralization and ELISA titers following receipt of inactivated influenza vaccine delivered by microneedle patch (administered by study staff or self- administered) and compare to inactivated influenza vaccine delivered by hypodermic needle (administered by study staff).\n\nTo evaluate HAI +/- microneutralization and ELISA titers following receipt of inactivated influenza vaccine delivered by microneedle patch (administered by study staff) and compare to inactivated Influenza vaccine delivered by microneedle patch (self-administered).\n\nTo evaluate T follicular helper cells following receipt of inactivated influenza vaccine delivered by microneedle patch (administered by study staff or self-administered) and compare to inactivated influenza vaccine delivered by hypodermic needle (administered by study staff).\n\nTo evaluate innate immunity signatures by microarrays following receipt of inactivated influenza vaccine delivered by microneedle patch (administered by study staff or self-administered) and compare to inactivated influenza vaccine delivered by hypodermic needle (administered by study staff).\n\nTo evaluate B memory cells, CD4 and CD8 central memory and effector T cells, intracellular cytokine staining (ICS) for interferon-gamma and interleukin-4, cross reactive T cells following receipt of inactivated influenza vaccine delivered by microneedle patch (administered by study staff or self- administered) and compare to inactivated influenza vaccine delivered by hypodermic needle (administered by study staff).\n\nTo evaluate the acceptability of inactivated Influenza vaccine delivered by microneedle patch (administered by study staff or self-administered) and compare to inactivated influenza vaccine delivered by hypodermic needle (administered by study staff).\n\nSchematic of Study Design:\n\nThis is a single center, partially blinded, randomized phase I study in which healthy adult subjects (ages 18-49) will receive either inactivated influenza vaccine (IIV) (either by microneedle patch or hypodermic needle) or placebo (by microneedle patch). This study is designed to investigate the safety, reactogenicity, acceptability and immunogenicity of an inactivated influenza vaccine delivered by microneedle patch.\n\nA total of 100 subjects (25 subjects in each group) will be randomized to one of four groups as in the schematic of the study design below.\n\nGroup A: Inactivated influenza vaccine delivered by microneedle patch administered by study staff Group B: Inactivated influenza vaccine delivered by intramuscular injection administered by study staff Group C: Inactivated influenza vaccine delivered by microneedle patch administered by subject Group D: Placebo delivered by microneedle patch and administered by study staff\n\nEach subject will have 6 clinic visits: D0, D2 (+1 day), D8 (+2 days), D28 (+/- 2 days), D56 (+/- 5 days), and D180( +/- 14 days).\n\nBlood draws will be obtained at 6 clinic visits to evaluate for immunogenicity (D0, D2 (+1 day) D8 (+ 2 days) - D28 (+/- 2 days), D56 (+/- 5 days), and D180 (+/- 14 days)) and at four clinic visits for safety (D0, D2 (+1 day), D8 (+2 days), and D28 (+/- 2 days)).\n\nSafety will be measured by the occurrence of solicited injection site and systemic reactogenicity on the day of study product administration through 7 days after, and serious adverse events (SAEs) and new-onset chronic medical conditions through 180 days after study product administration.\n\nImmunogenicity testing will include performing hemagglutination inhibition (HAI) +/- microneutralizing antibody assays as well as other adaptive immune assays on D0 prior to study product administration and at D8 (+2 days) , D28 (+/- 2 days), D56 (+/-5 days), and D180 (+/-14 days)) ."},"conditionsModule":{"conditions":["Influenza"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"SINGLE","whoMasked":["INVESTIGATOR"]}},"enrollmentInfo":{"count":100,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"IIV delivered by MN patch by study staff","type":"EXPERIMENTAL","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff","interventionNames":["Biological: Inactivated influenza vaccine"]},{"label":"IIV delivered IM by study staff","type":"ACTIVE_COMPARATOR","description":"Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff","interventionNames":["Biological: Inactivated influenza vaccine"]},{"label":"IIV delivered by MN patch by subject","type":"EXPERIMENTAL","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject","interventionNames":["Biological: Inactivated influenza vaccine"]},{"label":"Placebo MN patch by study staff","type":"PLACEBO_COMPARATOR","description":"Placebo delivered by microneedle patch administered by study staff","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Inactivated influenza vaccine","description":"Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season","armGroupLabels":["IIV delivered IM by study staff","IIV delivered by MN patch by study staff","IIV delivered by MN patch by subject"]},{"type":"OTHER","name":"Placebo","armGroupLabels":["Placebo MN patch by study staff"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Occurrence of Solicited Injection Site and Systemic Reactogenicity on the Day of Study Product Administration Through 7 Days After Administration.","description":"Safety will be measured by the occurrence of solicited injection site and systemic reactogenicity on the day of study product administration through 7 days after, and serious adverse events (SAEs) and new-onset chronic medical conditions through 180 days after study product administration. Local and systemic reactions were graded using an Injection Site Reaction table listing local reactions (e.g., swelling, erythema, etc.) and grade levels from 0 to 4 for each local reaction, a General Adverse Reaction table listing systemic reactions (e.g., fatigue, myalgia, etc.) and grade levels from 0 to 4 for each systemic reaction, and a Clinical Adverse Event Grading Scale (grades 1-4) for safety labs. In all tables, the higher the grade, the worse the adverse event.","timeFrame":"From Day 0 through Day 8"},{"measure":"Occurrence of Study Product-related Serious Adverse Events From D0 Until D180 (+/- 14 Days) After Study Product Administration.","timeFrame":"From Day 0 until Day 180"},{"measure":"Occurrence of Grade 3 Solicited or Unsolicited Adverse Events From D0 Until D28 (+/- 2 Days) After Study Product Administration.","timeFrame":"From Day 0 until Day 28"}],"secondaryOutcomes":[{"measure":"Geometric Mean Titer (GMT) of HAI Antibody Approximately 28 Days Following Receipt of IIV Delivered by Microneedle Patch or by Hypodermic Needle (Both Vaccines Administered by Study Staff).","timeFrame":"At Day 28"},{"measure":"Percentage of Subjects Achieving Seroprotection (Defined as a HAI Antibody Titer of 1:40 or Greater) Approximately 28 Days Following Receipt of IIV Delivered by Microneedle Patch or by Hypodermic Needle (Both Vaccines Administered by Study Staff).","timeFrame":"At Day 28"},{"measure":"Percentage of Subjects Achieving Seroconversion Approximately 28 Days Following Receipt of IIV Delivered by Microneedle Patch or by Hypodermic Needle (Both Vaccines Administered by Study Staff).","description":"Seroconversion is defined as either a pre-vaccination HAI titer \\<1:10 and a post-vaccination HAI titer ≥1:40, or a pre-vaccination HAI titer ≥1:10 and a minimum four-fold rise in post-vaccination HAI antibody titer.","timeFrame":"At Day 28"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject provides written informed consent prior to any study procedures being performed.\n2. Subject is male or non-pregnant female between the ages of 18 and 49, inclusive, on the day of signing informed consent.\n3. Subject is in good health as determined by vital signs, medical history and targeted physical examination\n4. Women of childbearing potential must agree to practice abstinence from sexual intercourse with men or use acceptable contraception, initiated at least 30 days prior to the study vaccination throughout D180 in order to avoid pregnancy.\n5. Women of childbearing potential must have a negative urine pregnancy test prior to administration of the study product.\n6. Subject is able to understand and comply with required study procedures.\n\nExclusion Criteria:\n\n1. Subject has received a 2014-2015 seasonal influenza vaccine.\n2. Subject with documented influenza infection during the 2014-2015 influenza season.\n3. Subject has touched or handled a microneedle patch prior to study enrollment (excluding dermaroller-like devices).\n4. Subject has a known allergy to eggs, egg or chicken protein or other components of the study product\n5. Subject has a history of severe reactions following previous immunization with licensed influenza virus vaccines.\n6. Subject has an acute illness with fever (temperature \\>100.4 °F) within 72 hours prior to vaccination.\n7. Subject has a known chronic medical problem\n8. Subject has known immunosuppression due to underlying illness or treatment\n9. Subject has a scar, tattoo, rash or other dermatologic condition in the area of the vaccination site which will interfere with the assessment of injection site reactogenicity.\n10. Subject has a history of keloid formation.\n11. Subject has used long-term\\* high-dose\\*\\* oral or parenteral glucocorticoids, or high-dose inhaled steroids\\*\\*\\*.\n\n    * Long term is defined as taken for 2 weeks or more in total at any time during the past 2 months.\n    * High dose defined as prednisone ≥ 20 mg total daily dose, or equivalent dose of other glucocorticoids.\n    * High dose defined as \\> 800 mcg/day of beclomethasone dipropionate or equivalent.\n\n    If short term corticosteroids are given, then the subject should not receive study vaccination or have blood collected for immunogenicity studies within 1 week of steroid administration\n12. Subject has a history of Guillain-Barre Syndrome.\n13. Subject is pregnant, post-partum (\\<12 months after delivery), or breast feeding or plans to breastfeed during the study.\n14. Alcohol or drug abuse and psychiatric conditions that, in the opinion of the investigator, would preclude compliance with the trial or interpretation of safety or endpoint data.\n15. Subject has any condition that, in the opinion of the investigator, may put the subject at increased risk of harm, may cause the subject to be unable to meet the requirements or might otherwise interfere with evaluations required by the study.\n16. Subject has received any experimental products within 30 days before study entry or plan to receive experimental products at any time during the study.\n17. Subject has received a live vaccine within 28 days prior to study entry or plans to receive a live vaccine prior to Day 28 of the study.\n18. Subject has received an inactivated vaccine within 14 days prior to study entry or plans to receive an inactivated vaccine prior to Day 28 of the study.\n19. Subject has received immunoglobulin or blood products in the past 90 days or planned receipt at any time during the study.\n20. Subject BMI \\>35 kg/m2.\n21. Subject has a systolic blood pressure \\>160 or \\< 80 mmHg or diastolic blood pressure \\>100 or \\< 60 mmHg.\n22. Subject has a resting pulse rate \\< 50 bpm or \\>100 bpm.\n23. Subject donated blood 56 days before screening OR will donate blood on or before day 28 of the study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Nadine Rouphael, MD","affiliation":"Emory University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"The Hope Clinic","city":"Decatur","state":"Georgia","zip":"30030","country":"United States","geoPoint":{"lat":33.77483,"lon":-84.29631}}]},"referencesModule":{"references":[{"pmid":"28666680","type":"DERIVED","citation":"Rouphael NG, Paine M, Mosley R, Henry S, McAllister DV, Kalluri H, Pewin W, Frew PM, Yu T, Thornburg NJ, Kabbani S, Lai L, Vassilieva EV, Skountzou I, Compans RW, Mulligan MJ, Prausnitz MR; TIV-MNP 2015 Study Group. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet. 2017 Aug 12;390(10095):649-658. doi: 10.1016/S0140-6736(17)30575-5. Epub 2017 Jun 27."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"IIV Delivered by MN Patch by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"FG001","title":"IIV Delivered IM by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"FG002","title":"IIV Delivered by MN Patch by Subject","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"FG003","title":"Placebo MN Patch by Study Staff","description":"Placebo delivered by microneedle patch administered by study staff\n\nPlacebo"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"25"},{"groupId":"FG002","numSubjects":"25"},{"groupId":"FG003","numSubjects":"25"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"25"},{"groupId":"FG002","numSubjects":"25"},{"groupId":"FG003","numSubjects":"25"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"IIV Delivered by MN Patch by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"BG001","title":"IIV Delivered IM by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"BG002","title":"IIV Delivered by MN Patch by Subject","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"BG003","title":"Placebo MN Patch by Study Staff","description":"Placebo delivered by microneedle patch administered by study staff\n\nPlacebo"},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"25"},{"groupId":"BG004","value":"100"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"25"},{"groupId":"BG004","value":"100"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"47"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"53"}]}]}]},{"title":"Race/Ethnicity, Customized","populationDescription":"The different rows describe subsets of the population and the numbers add up to the overall number (100 subjects)","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"49"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"31"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"20"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Occurrence of Solicited Injection Site and Systemic Reactogenicity on the Day of Study Product Administration Through 7 Days After Administration.","description":"Safety will be measured by the occurrence of solicited injection site and systemic reactogenicity on the day of study product administration through 7 days after, and serious adverse events (SAEs) and new-onset chronic medical conditions through 180 days after study product administration. Local and systemic reactions were graded using an Injection Site Reaction table listing local reactions (e.g., swelling, erythema, etc.) and grade levels from 0 to 4 for each local reaction, a General Adverse Reaction table listing systemic reactions (e.g., fatigue, myalgia, etc.) and grade levels from 0 to 4 for each systemic reaction, and a Clinical Adverse Event Grading Scale (grades 1-4) for safety labs. In all tables, the higher the grade, the worse the adverse event.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Reactions","timeFrame":"From Day 0 through Day 8","groups":[{"id":"OG000","title":"IIV Delivered by MN Patch by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"OG001","title":"IIV Delivered IM by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"OG002","title":"IIV Delivered by MN Patch by Subject","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"OG003","title":"Placebo MN Patch by Study Staff","description":"Placebo delivered by microneedle patch administered by study staff\n\nPlacebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"25"}]}],"classes":[{"title":"Reactions D1-D7 (pruritus)","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"4"}]}]},{"title":"Reactions D1-D7 (Pain)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"}]}]},{"title":"Reactions D1-D7 (Redness/Erythema)","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"0"}]}]},{"title":"Reactions D1-D7 (Tenderness)","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"4"}]}]},{"title":"Reactions D1-D7 (Nausea)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Reactions D1-D7 (Fatigue)","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"}]}]},{"title":"Reactions D1-D7 (Headache)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"2"}]}]},{"title":"Reactions D1-D7 (Swelling/Induration)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Reactions D1-D7 (Myalgia)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"}]}]},{"title":"Reactions D1-D7 (Shivering/Shaking)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Reactions D1-D7 (Arthralgia)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}]}]},{"title":"Reactions D1-D7 (Fever)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Reactions D1-D7 (Malaise)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Reactions D1-D7 (Sweating)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Occurrence of Study Product-related Serious Adverse Events From D0 Until D180 (+/- 14 Days) After Study Product Administration.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Serious adverse events","timeFrame":"From Day 0 until Day 180","groups":[{"id":"OG000","title":"IIV Delivered by MN Patch by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"OG001","title":"IIV Delivered IM by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"OG002","title":"IIV Delivered by MN Patch by Subject","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"OG003","title":"Placebo MN Patch by Study Staff","description":"Placebo delivered by microneedle patch administered by study staff\n\nPlacebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Occurrence of Grade 3 Solicited or Unsolicited Adverse Events From D0 Until D28 (+/- 2 Days) After Study Product Administration.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Grade 3 adverse events","timeFrame":"From Day 0 until Day 28","groups":[{"id":"OG000","title":"IIV Delivered by MN Patch by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"OG001","title":"IIV Delivered IM by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"OG002","title":"IIV Delivered by MN Patch by Subject","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season"},{"id":"OG003","title":"Placebo MN Patch by Study Staff","description":"Placebo delivered by microneedle patch administered by study staff\n\nPlacebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of HAI Antibody Approximately 28 Days Following Receipt of IIV Delivered by Microneedle Patch or by Hypodermic Needle (Both Vaccines Administered by Study Staff).","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"HAI Antibody Titers (GMT)","timeFrame":"At Day 28","groups":[{"id":"OG000","title":"IIV Delivered by MN Patch by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff"},{"id":"OG001","title":"IIV Delivered IM by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}]}],"classes":[{"title":"A/Christchurch (H1N1)","categories":[{"measurements":[{"groupId":"OG000","value":"1197","lowerLimit":"854.6","upperLimit":"1675"},{"groupId":"OG001","value":"997.3","lowerLimit":"703","upperLimit":"1415"}]}]},{"title":"A/Texas (H3N2)","categories":[{"measurements":[{"groupId":"OG000","value":"287","lowerLimit":"191.5","upperLimit":"430.2"},{"groupId":"OG001","value":"223.2","lowerLimit":"159.8","upperLimit":"311.7"}]}]},{"title":"B/Massachusetts","categories":[{"measurements":[{"groupId":"OG000","value":"125.8","lowerLimit":"85.92","upperLimit":"184.1"},{"groupId":"OG001","value":"94.48","lowerLimit":"73.5","upperLimit":"121.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Seroprotection (Defined as a HAI Antibody Titer of 1:40 or Greater) Approximately 28 Days Following Receipt of IIV Delivered by Microneedle Patch or by Hypodermic Needle (Both Vaccines Administered by Study Staff).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of subjects (seroprotected)","timeFrame":"At Day 28","groups":[{"id":"OG000","title":"IIV Delivered by MN Patch by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff"},{"id":"OG001","title":"IIV Delivered IM by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}]}],"classes":[{"title":"A/Christchurch (H1N1)","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"85.8","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"86.3","upperLimit":"100"}]}]},{"title":"A/Texas (H3N2)","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"85.8","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"86.3","upperLimit":"100"}]}]},{"title":"B/Massachusetts","categories":[{"measurements":[{"groupId":"OG000","value":"96","lowerLimit":"78.9","upperLimit":"99.9"},{"groupId":"OG001","value":"100","lowerLimit":"86.3","upperLimit":"100"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Seroconversion Approximately 28 Days Following Receipt of IIV Delivered by Microneedle Patch or by Hypodermic Needle (Both Vaccines Administered by Study Staff).","description":"Seroconversion is defined as either a pre-vaccination HAI titer \\<1:10 and a post-vaccination HAI titer ≥1:40, or a pre-vaccination HAI titer ≥1:10 and a minimum four-fold rise in post-vaccination HAI antibody titer.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of subjects who seroconverted","timeFrame":"At Day 28","groups":[{"id":"OG000","title":"IIV Delivered by MN Patch by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff"},{"id":"OG001","title":"IIV Delivered IM by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}]}],"classes":[{"title":"A/Christchurch (H1N1)","categories":[{"measurements":[{"groupId":"OG000","value":"92","lowerLimit":"73","upperLimit":"99"},{"groupId":"OG001","value":"80","lowerLimit":"59.3","upperLimit":"93.2"}]}]},{"title":"A/Texas (H3N2)","categories":[{"measurements":[{"groupId":"OG000","value":"83","lowerLimit":"62.6","upperLimit":"95.3"},{"groupId":"OG001","value":"76","lowerLimit":"54.9","upperLimit":"90.6"}]}]},{"title":"B/Massachusetts","categories":[{"measurements":[{"groupId":"OG000","value":"71","lowerLimit":"48.9","upperLimit":"87.4"},{"groupId":"OG001","value":"32","lowerLimit":"15","upperLimit":"53.5"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","eventGroups":[{"id":"EG000","title":"IIV Delivered by MN Patch by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season","deathsNumAffected":0,"deathsNumAtRisk":25,"seriousNumAffected":0,"seriousNumAtRisk":25,"otherNumAffected":23,"otherNumAtRisk":25},{"id":"EG001","title":"IIV Delivered IM by Study Staff","description":"Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season","deathsNumAffected":0,"deathsNumAtRisk":25,"seriousNumAffected":0,"seriousNumAtRisk":25,"otherNumAffected":20,"otherNumAtRisk":25},{"id":"EG002","title":"IIV Delivered by MN Patch by Subject","description":"Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject\n\nInactivated influenza vaccine: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season","deathsNumAffected":0,"deathsNumAtRisk":25,"seriousNumAffected":1,"seriousNumAtRisk":25,"otherNumAffected":23,"otherNumAtRisk":25},{"id":"EG003","title":"Placebo MN Patch by Study Staff","description":"Placebo delivered by microneedle patch administered by study staff\n\nPlacebo","deathsNumAffected":0,"deathsNumAtRisk":25,"seriousNumAffected":0,"seriousNumAtRisk":25,"otherNumAffected":12,"otherNumAtRisk":25}],"seriousEvents":[{"term":"Severe acute enteritis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"severe acute enteritis (i.e. abdominal pain, nausea, and vomiting)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]}],"otherEvents":[{"term":"Swelling/Induration (grade 1)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Redness/Erythema (grade 1)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":8,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Tenderness (grade 1)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":25},{"groupId":"EG001","numAffected":9,"numAtRisk":25},{"groupId":"EG002","numAffected":14,"numAtRisk":25},{"groupId":"EG003","numAffected":3,"numAtRisk":25}]},{"term":"Pain (grade 1)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":25},{"groupId":"EG001","numAffected":8,"numAtRisk":25},{"groupId":"EG002","numAffected":4,"numAtRisk":25},{"groupId":"EG003","numAffected":2,"numAtRisk":25}]},{"term":"Pruritis (itching) (grade 1)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":25},{"groupId":"EG001","numAffected":3,"numAtRisk":25},{"groupId":"EG002","numAffected":20,"numAtRisk":25},{"groupId":"EG003","numAffected":4,"numAtRisk":25}]},{"term":"Fatigue","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":25},{"groupId":"EG001","numAffected":7,"numAtRisk":25},{"groupId":"EG002","numAffected":2,"numAtRisk":25},{"groupId":"EG003","numAffected":5,"numAtRisk":25}]},{"term":"Body ache (myalgia) (grade 1)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":25},{"groupId":"EG001","numAffected":6,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":3,"numAtRisk":25}]},{"term":"Shivering/shaking body movements (grade 1)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Sweating (grade 1)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25},{"groupId":"EG001","numAffected":5,"numAtRisk":25},{"groupId":"EG002","numAffected":2,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Malaise (grade 1)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":25},{"groupId":"EG001","numAffected":2,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Nausea (grade 1)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25},{"groupId":"EG001","numAffected":3,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":6,"numAtRisk":25}]},{"term":"Fever (grade 1)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":6,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Joint pain (arthralgia) (grade 1)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":2,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Anemia (grade 1)","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":25},{"groupId":"EG001","numAffected":2,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":3,"numAtRisk":25}]},{"term":"Decreased absolute lymphocytes (grade 1)","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Leukocytosis (grade 1)","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Leukopenia (grade 1)","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":3,"numAtRisk":25}]},{"term":"Thrombocytopenia (grade 1)","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Gastroenteritis (grade 1)","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Epigastric pain (grade 1)","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"URI (grade 1)","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":2,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Elevated ALT (grade 1)","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":2,"numAtRisk":25}]},{"term":"Transaminitis (grade 1)","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Elevated CK (grade 1)","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Left elbow tendonitis (grade 1)","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Neck pain (grade 1)","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Arthralgia (grade 1)","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":2,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Leg pain (grade 1)","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Headache (grade 1)","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":6,"numAtRisk":25},{"groupId":"EG002","numAffected":6,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Tooth infection (grade 1)","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Toe infection (grade 1)","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Conjunctivitis (grade 1)","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Presyncope (grade 1)","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Hypertension (grade 1)","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Elevated ALT AST (grade 1)","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Redness/Erythema (grade 2)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":2,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Tenderness (grade 2)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":25},{"groupId":"EG001","numAffected":6,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Pruritis (grade 2)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Fatigue (grade 2)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":25},{"groupId":"EG001","numAffected":2,"numAtRisk":25},{"groupId":"EG002","numAffected":2,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Pain (grade 2)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":3,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Body ache (myalgia) (grade 2)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Shivering/shaking Body Movements (grade 2)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Malaise (grade 2)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":3,"numAtRisk":25},{"groupId":"EG002","numAffected":3,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Joint pain (Arthralgia) (grade 2)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Nausea (grade 2)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Swelling/Induration (grade 2)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Neutropenia (grade 2)","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":2,"numAtRisk":25}]},{"term":"Thrombocytopenia (grade 2)","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Headache (grade 2)","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Vomiting (grade 2)","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Arthralgia (grade 2)","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Left hand bruise (grade 2)","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Hypertension (grade 2)","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Pruritis (grade 3)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Fatigue (grade 3)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Elevated ALT (grade 3)","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Tenderness (grade 3)","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Acute enteritis","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Headache (grade 3)","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Hypertension (grade 3)","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":0,"numAtRisk":25},{"groupId":"EG003","numAffected":1,"numAtRisk":25}]},{"term":"Elevated AST (grade 4)","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]},{"term":"Elevated CK (grade 4)","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25},{"groupId":"EG001","numAffected":0,"numAtRisk":25},{"groupId":"EG002","numAffected":1,"numAtRisk":25},{"groupId":"EG003","numAffected":0,"numAtRisk":25}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Mark Prausnitz, PhD","organization":"Georgia Tech","email":"prausnitz@gatech.edu","phone":"404-894-5135"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}